SCHEMBL1248211

SCHEMBL1248211

OC12CCCC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19122443 1.00
SCHEMBL11945785 1.00
SCHEMBL17057746 1.00
SCHEMBL1250966 0.92
Isobutane SCHEMBL20607555 0.90 ALDH1A1 (0.33)
SCHEMBL14473055 0.89 MET (0.37)
SCHEMBL1249492 0.81
SCHEMBL1251080 0.78
SCHEMBL7924907 0.77 OPRM1 (0.39)
SCHEMBL18231432 0.76 ACHE (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024098273-A1 ANTI-INFLUENZA VIRUS PHOSPHATE ESTER COMPOUND AND USE THEREOF 石家庄迪斯凯威医药科技有限公司 2024-05-16 WO disclosed
WO-2024098856-A1 ANTI-INFLUENZA-VIRUS DERIVATIVES AND USE THEREOF 石家庄迪斯凯威医药科技有限公司 2024-05-16 WO disclosed
US-11673864-B2 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-13 US disclosed
EP-4110782-A1 COMPOUNDS AS CDK2/4/6 INHIBITORS Fochon Biosciences, Ltd. (CN) 2023-01-04 EP disclosed
CN-115551856-A Compounds as CDK2/4/6 inhibitors 重庆复尚源创医药技术有限公司 2022-12-30 CN disclosed
US-20210047271-A1 PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2021-02-18 US disclosed
US-10738009-B2 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-08-11 US disclosed
US-20190248745-A1 PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2019-08-15 US disclosed
US-10087143-B2 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-10-02 US disclosed
WO-2018081276-A1 COMPOUNDS TESARO, INC. (US) 2018-05-03 WO disclosed
US-20090209580-A1 ANTITUMOR AGENT FOR THYROID CANCER EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-20 US disclosed
US-20090203693-A1 THERAPEUTIC AGENT FOR LIVER FIBROSIS EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-13 US disclosed
US-20090053236-A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-02-26 US disclosed
CN-101253140-A Process for the preparation of bicyclo [3.1.0] hexanols MERCK SHARP & DOHME (GB) 2008-08-27 CN disclosed
EP-1925676-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 EP disclosed
EP-1925941-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 EP disclosed
EP-1912924-A1 A PROCESS FOR THE PREPARATION OF BICYCLO[3.1.0]HEXANOLS Merck Sharp & Dohme Limited (GB) 2008-04-23 EP disclosed
EP-1797877-A1 JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR Eisai Co., Ltd. (JP) 2007-06-20 EP disclosed
WO-2007015111-A1 A PROCESS FOR THE PREPARATION OF BICYCLO[3.1.0]HEXANOLS MERCK SHARP & DOHME LIMITED (GB) 2007-02-08 WO disclosed
US-20060135486-A1 Use of sulfonamide-including compounds in combination with angiogenesis inhibitors EISAI CO., LTD. (JP) 2006-06-22 US disclosed